The FDA database lists a supplement dated 8 October 2026 to abbreviated new drug application 209040 for tafluprost, held by Sandoz. Tafluprost is a prostaglandin analogue eye drop used to lower intraocular pressure in glaucoma and ocular hypertension.
The record does not state what the supplement changes. Supplements to generic applications usually concern manufacturing, labelling or packaging and are administrative.
There is no new safety communication, and nothing in this record changes how tafluprost is prescribed. Its availability in India depends on CDSCO approval and local supply, not on this FDA action.
- This is an FDA supplement to a generic tafluprost application, not a new approval.
- The record does not describe the change.
- No safety warning accompanies it.
- Prescribing of prostaglandin analogues is unchanged.
Why it matters
It confirms ongoing generic activity for a glaucoma drop, with no clinical signal.
Don't overread it
A supplement to a generic application is not a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for ophthalmology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free